Patent ID: 11866490
Assignee: HOFFMANN-LA ROCHE, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method for decreasing the rate of ocular disease progression in an individual having the ocular disease, comprising administering to the individual a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to human VEGF and to human IL-1beta, wherein the antibody comprises a VEGF paratope and an IL-1beta paratope within one cognate pair of a variable light chain domain (VL domain) and a variable heavy chain domain (VH domain), wherein the VEGF paratope comprises amino acid residues from CDR-H2, CDR-L1 and CDR-L3 of the antibody that binds to human VEGF, wherein the IL-1beta paratope comprises amino acid residues from the CDR-H1, CDR-H3 and CDR-L2 of the antibody that binds to human IL-1beta, wherein the antibody or antigen-binding fragment thereof comprises a VH domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 13, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 14, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 15, and a VL domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 16, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 17, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 8, and wherein the administering decreases the rate of ocular disease progression in the individual, wherein the ocular disease is selected from the group consisting of age-related macular degeneration (AMD), geographic atrophy (GA), macular degeneration, macular edema, diabetic macular edema (DME), retinopathy, and diabetic retinopathy (DR).